BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach